Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Trevi Therapeutics

02/05/2025 13:15

Trevi Therapeutics Inc TRVI.OQ TRVI.O is expected to show no change in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

​LSEG's mean analyst estimate for Trevi Therapeutics Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.9% in the last three months. ​

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $20.00​, above​ its last closing price of $6.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.12
-0.12
-0.11
Beat
7.5
Sep. 30 2024
-0.12
-0.12
-0.13
Missed
-9.8
Jun. 30 2024
-0.10
-0.11
-0.12
Missed
-13.2​
Mar. 31 2024
-0.09
-0.09
-0.11
Missed
-25
​​Dec. 31 2023
-0.09
-0.08
Beat
12.7
Sep. 30 2023
-0.09
-0.09
-0.08
Beat
12.7​
Jun. 30 2023
-0.09
-0.08
-0.07
Beat
17.6
Mar. 31 2023
-0.07
-0.07
-0.06
Beat
18.2

This summary was machine generated May 2 at 12:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)